Izotropic Corporation (IZO.CN)
| Previous Close | 0.1350 |
| Open | 0.0000 |
| Bid | 0.1150 x 0 |
| Ask | 0.1450 x 0 |
| Day's Range | 0.0000 - 0.0000 |
| 52 Week Range | |
| Volume | |
| Avg. Volume | 27,602 |
| Market Cap | 6.325M |
| Beta (5Y Monthly) | 2.03 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0500 |
| Earnings Date | Apr 02, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Newsfile
Izotropic Receives Response From U.S. FDA
Vancouver, British Columbia--(Newsfile Corp. - January 30, 2024) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company commercializing IzoView, a CT (computed tomography) imaging system, that produces images of anatomy for non-invasive characterization of tissue with an application in breast imaging, announces that further to its January 8th disclosure, it has received a response from the U.S. FDA. The FDA's mammogram and ultrasound
- Newsfile
Izotropic Provides Regulatory and Operational Updates
Vancouver, British Columbia--(Newsfile Corp. - January 8, 2024) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company commercializing IzoView, a CT (computed tomography) imaging system, that produces images of anatomy for non-invasive characterization of tissue with an application in breast imaging, provides an update on its regulatory status with the U.S. Food and Drug Administration ("FDA") and operational activities. FDA Regulato
- Newsfile
Izotropic Completes Pre-Submission Meeting with U.S. FDA
Vancouver, British Columbia--(Newsfile Corp. - November 1, 2023) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company commercializing IzoView, a CT (computed tomography) imaging system, that produces images of anatomy for non-invasive tissue characterization with an application in breast imaging, announced today that it completed its previously announced pre-submission meeting with the U.S. FDA.The purpose of the meeting was to dis
